These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 18195210)

  • 1. Preattack vaccination against anthrax may be cost-effective in certain populations.
    Hopkins RJ; Waytes TA; Zink TK
    Arch Intern Med; 2008 Jan; 168(1):114-5; author reply 115. PubMed ID: 18195210
    [No Abstract]   [Full Text] [Related]  

  • 2. Responding to a small-scale bioterrorist anthrax attack: cost-effectiveness analysis comparing preattack vaccination with postattack antibiotic treatment and vaccination.
    Schmitt B; Dobrez D; Parada JP; Kyriacou DN; Golub RM; Sharma R; Bennett C
    Arch Intern Med; 2007 Apr; 167(7):655-62. PubMed ID: 17420423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioterrorism: what level is the threat and are vaccines the answer?
    Smith LA
    Expert Rev Vaccines; 2004 Oct; 3(5):493-5. PubMed ID: 15485326
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-effectiveness of defending against bioterrorism: a comparison of vaccination and antibiotic prophylaxis against anthrax.
    Fowler RA; Sanders GD; Bravata DM; Nouri B; Gastwirth JM; Peterson D; Broker AG; Garber AM; Owens DK
    Ann Intern Med; 2005 Apr; 142(8):601-10. PubMed ID: 15838066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Summaries for patients. What is the most cost-effective way to protect people in the event of an anthrax terror attack?
    Ann Intern Med; 2005 Apr; 142(8):I40. PubMed ID: 15838060
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness comparison of response strategies to a large-scale anthrax attack on the chicago metropolitan area: impact of timing and surge capacity.
    Kyriacou DN; Dobrez D; Parada JP; Steinberg JM; Kahn A; Bennett CL; Schmitt BP
    Biosecur Bioterror; 2012 Sep; 10(3):264-79. PubMed ID: 22845046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccines: countering anthrax: vaccines and immunoglobulins.
    Grabenstein JD
    Clin Infect Dis; 2008 Jan; 46(1):129-36. PubMed ID: 18171228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A no-show vaccine--for a mere $126 million. Deal?
    Pound ET
    US News World Rep; 2001 Oct; 131(18):16. PubMed ID: 11699229
    [No Abstract]   [Full Text] [Related]  

  • 9. Potential biological targets of Bacillus anthracis in anti-infective approaches against the threat of bioterrorism.
    Bouzianas DG
    Expert Rev Anti Infect Ther; 2007 Aug; 5(4):665-84. PubMed ID: 17678429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Being prepared: modeling the response to an anthrax attack.
    Webb GF
    Ann Intern Med; 2005 Apr; 142(8):667-8. PubMed ID: 15838074
    [No Abstract]   [Full Text] [Related]  

  • 11. Engineered chloroplasts as vaccine factories to combat bioterrorism.
    Streatfield SJ
    Trends Biotechnol; 2006 Aug; 24(8):339-42. PubMed ID: 16815579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioterrorism: what is and what may never be. Part 1.
    Emmons W
    Del Med J; 2002 May; 74(5):219-25. PubMed ID: 12063832
    [No Abstract]   [Full Text] [Related]  

  • 13. [Evaluation of anthrax vaccination in Denmark].
    Bork KH; Heegaard ED; Nielsen J; Kogutowska E; Heegaard NH
    Ugeskr Laeger; 2005 Sep; 167(36):3390-3. PubMed ID: 16159489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-effectiveness of strategies to reduce mortality from an intentional release of aerosolized anthrax spores.
    Braithwaite RS; Fridsma D; Roberts MS
    Med Decis Making; 2006; 26(2):182-93. PubMed ID: 16525172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioterrorism and compulsory vaccination: United States continues vaccinating to keep troops healthy.
    Grabenstein JD; Winkenwerder W
    BMJ; 2004 Oct; 329(7472):977; author reply 977. PubMed ID: 15499123
    [No Abstract]   [Full Text] [Related]  

  • 16. Public health response to an anthrax attack: an evaluation of vaccination policy options.
    Baccam P; Boechler M
    Biosecur Bioterror; 2007 Mar; 5(1):26-34. PubMed ID: 17437349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anthrax--where does the real threat lie?
    Senior K
    Lancet Infect Dis; 2012 Jun; 12(6):436-7. PubMed ID: 22811982
    [No Abstract]   [Full Text] [Related]  

  • 18. Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis.
    Tournier JN; Ulrich RG; Quesnel-Hellmann A; Mohamadzadeh M; Stiles BG
    Expert Rev Anti Infect Ther; 2009 Mar; 7(2):219-36. PubMed ID: 19254170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies for defense against biological attack.
    Casadevall A
    Nat Biotechnol; 2002 Feb; 20(2):114. PubMed ID: 11821846
    [No Abstract]   [Full Text] [Related]  

  • 20. Confusion in spades. The anthrax scares reveal a public-health system in disarray.
    Spake A
    US News World Rep; 2001 Oct; 131(18):42-8. PubMed ID: 11699231
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.